Inflammation of the Pleura is called Pleurisy. In dry Pleurisy, the pleural surfaces are inflamed without fluid in in the middle of them. In many cases pleurisy is connected with effusion. Both dry pleurisy and pleural effusion may form at different stages of the same disease process.

Dry or fibrinous pleurisy: The pleura gets involved from the disease of the fundamental lung. Trauma to the chest may also lead to Pleurisy. The suggestive symptom is the catching pain felt acutely over the affected area by inspiratory movements brought about by deep breathing, coughing or sneezing. Its etiology are as follows: Pulmonary tuberculosis, Pneumonia, bronchogenic carcinoma, pulmonary infarction, connective tissue disorders (such as systemic lupus erythematosus, polyarteritis nodosa, and rheumatoid disease), rheumatic fever, viral infections (especially Coxsackie [Bornholm disease), hepatopulmonary amoebiasis, and uraemia.

Lung Aspiration

The corporal test reveals diminution of movement on the affected side and the presence of pleural friction rub on auscultation. Pleural rub has a superficial grafting quality. The rub is heard best by polite pressure of the chest piece of the stethoscope on the chest wall. Unlike rales, it is not altered by coughing. With the improvement of pleural effusion, the rub may disappear in most cases. Pleural rub has to be distinguished from crepitations and sounds arising from movements of the chest wall. Other painful conditions like Pneumonia, myocardial infarction, and herpes Zoster have to be differentiated from pleurisy.

Disease of the Pleura and Pulmonary Cysts

Malignant Mesothelioma: Pathogenesis, Diagnosis, and Translational Therapies Best

Rate This Product :

Malignant Mesothelioma: Pathogenesis, Diagnosis, and Translational Therapies Overview

Malignant Mesothelioma brings together the most current diagnostic criteria and treatment plans from the world’s leading experts on this rare but devastating cancer. The first edition was a critical and commercial success and this revision builds on that reputation. The editors have brought together the world’s leading experts to fully explore the latest scientific breakthroughs in carcinogenesis, immunotherapy, potential vaccination strategies, and gene therapy. The clinical aspects of the book are equally strong, with thorough discussion of epidemiology, etiology, different clinical presentations, imaging (including interventional pulmonology), treatment of benign disease, strategies for multimodality treatment of malignant disease.

Editors: Harvey I. Pass, M.D, Chief, Thoracic Surgery, New York University, New York, NY; Nicholas Vogelzang, M.D, Director, Nevada Cancer Institute, Las Vegas, NV; University of Chicago, Michele Carbone, M.D., Ph.D, Researcher and Director, Thoracic Oncology Program, Cancer Research Center of Hawaii, Honolulu, HI; and Anne S. Tsao, M.D, Department of Thoracic/Head & Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX.

Malignant Mesothelioma: Pathogenesis, Diagnosis, and Translational Therapies Specifications

Customer Reviews

*** Product Information and Prices Stored: Jan 09, 2012 14:32:27

Pleural effusion: In this condition, fluid accumulates in the middle of the two layers of the pleura. Normally, pleura contains only a small estimate of fluid. The pleural fluid remains in dynamic balance with blood. Movements of the lung favour the movement of the fluid in and out of the pleural space. In most of the disease states, absorption of the fluid is reduced. The fluid may be contained in the normal pleural space or it may be loculated in the interlobar fissure, infrapulmonary space or may remain adjacent to the mediastinum. The fluid progressively compresses the subjacent lung which undergoes collapse.

The improvement of symptoms depends upon the speed of accumulation of fluid and its quantity. Tasteless symptoms contain dyspnea, pleuritic pain, or symptoms of the fundamental disorder. High fever may occur in acute pyogenic infections. Tuberculosis may be connected with lower grades of fever. Pleural fluid is clinically detectable only when it is about 500ml in volume but radiologically it may be detected even when the volume is only 350 ml. A fully developed moderate or massive effusion reveals abundance of the intercostal spaces and restriction of respiratory movements of the same side. Midline structures are shifted to the opposite side. Percussion elicits stony deadness with the highest level in the axilla and lower levels in front and back (S-shaped curve of Ellis). This is the most constant corporal sign. The Traube's space, which is the area overlying the gas bubble or the stomach, is obliterated in left-sided effusion. Breath sounds, vocal femitus and vocal resonance are diminished or absent. Aegophony may be present above the level of effusion. At times bronchial breathing may be heard over a pleural effusion.

Complications include: Respiratory embarrassment, massive bilateral effusions which may be fatal due to respiratory failure, secondary infection of the pleural fluid which converts it into empyema, society of fibrin from the fluid on the exterior of the collapsed lung (cortication) that prevents re-expansion, and fibrosis of the pleura and obliteration of the pleural space (fibrothorax) which form as a sequel to long standing pleural effusions.

Radiographic appearance: If the fluid volume is small only the costophrenic angles are obliterated. As the fluid accumulates further, it throws a triangular lateral opacity blurring the hemidiaphragm. Large pleural effusions shift the midline structures to the opposite side. An interlobar effusion in the oblique fissure produces an elongated cigar-shaped shadow seen best in the lateral view. Fluid in the horizontal fissure throws a rounded shadow seen in the Pa-view. The term "vanishing pulmonary tumor" has been used for inter-lobar effusions since they clear up with treatment.
Character of the fluid: Pleural fluids may be transudates or exudates. They differ in corporal and biochemical nature. Transudate (Clear, often bilateral, does not clot on standing, definite gravity less than 1015, protein content less than 3g/dL, cells less than 100/Cmm). Exudate (Opalescent or turbid, unilateral, often clots on standing, above 1015, above 3g/dL, cell count is high).

Congestive Cardiac failure, nephrotic syndrome, hypoproteinemia, constrictive pericarditis, and myxedema may cause transudation into the pleura. Exudates are caused by tuberculosis, Pneumonias, Pulmonary infarction, bronchogenic carcinoma, Pleural secondaries, dyscollagenoses and hepatopulmonary amoebiasis. Rare causes contain subphrenic abscess, postmyocardial infarction syndrome and acute pancreatitis. Tuberculous effusion is straw-coloured. The fluid is hemorrhagic in malignancy and infarction and it is chylous (milky) in lymphatic obstruction due to filariasis and lymphomas. Variety of purulent fluid in the pleura is called empyema.

Microscopy: In acute bacterial infections, neutrophils predominate, lymphocytes predominate in tuberculosis. Eosinophils may predominate in dyscollagenoses and pulmonary infarction. test of a wet establishment stained by methylene blue reveals malignant cells in over 90% of cases of malignant effusions. Identification of the nature of the malignant cells is done by Papanicolaou's technique. The nature of chylous fluid is confirmed by demonstrating the presence of fat. Elevated amylase levels are suggestive of acute pancreatitis (500 units/ml of higher). Values of Ldh are raised in exudates. Gram-staining, Ziehl-Neelsen staining, and culture help in identifying the causative microbes. When investigations, pleural biopsy may be attempted. Extra (Cope's) needles are available for this purpose. Though a obvious biopsy is diagnostic, a negative biopsy does not exclude pleural malignancy.

Principles of treatment
Pleural effusion may rarely present as an emergency with respiratory embarrassment. In such cases, emergency measures are required to give relief-especially if the effusion is massive or bilateral. The fluid is aspirated by thoracentesis done in the eighth or ninth intercostal space in the posterior axillary line after anaesthetising the part. Enough fluid id removed to ease the distress. Whenever pleural fluid is aspirated, it is also subjected to diagnostic investigations.

Elective management
Medical therapy is instituted depending on clinical features and pleural fluid analysis. It is ideal to aspirate the fluid after instituting definite drug therapy. Aspiration is indicated: to make the diagnosis; to ease distress and to remove the exudate so as to hasten full rescue of the pleura and avoid complications. It is generally advisable to restrict the volume of fluid removed at one sitting to 1 Liter or less in order to avoid pulmonary edema. Aspiration has to be repeated at times. Two or three aspirations will be Enough in most of the cases of tuberculous effusion. In malignant pleural fluid tends to re-accumulate even after repeated aspirations. Drugs used to be instilled intra-pleurally with the hope of raising the local attention of the drug. Intra-pleural supervision of drugs my be required only in some rare cases, if proper systemic therapy is given. Sometimes aspiration of the pleural cavity may give rise to complications. These contain pleural shock, anaphylactic shock due to anaesthetic, bleeding into the pleural cavity, pulmonary edema, infection, and accidental introduction of air into the pleura.

Pulmonary Cysts
Cysts of the Lung may be congenital or acquired. Congenital cysts are of three varieties:
1. Bronchogenic-these may be solitary or multiple;
2. Alveolar cell types-these also may be solitary or multiple; and
3. Mixed types having elements of both bronchogenic and alveolar cysts.

These vary in size and may be unilateral or bilateral. They may be settled in any place in the lung. They are filled with fluid at birth, but air enter the cavity later when bronchial communications develop. The cyst may be thick- or thin- walled. Cystic disease of the Lung may occur in relationship with fibrocystic disease of the pancreas. This is Tasteless in Western countries, but is rare in Asia and Africa.

Acquired Cysts
These may be resent bullous emphysema, subpleural ysts or parasitic cysts, which contain hydratid disease and paragonimiasis. The severity of symptoms is thought about by the extent, size, time of diagnosis, and presence of complications. When the lung parenchyma is grossly reduced, respiratory embarrassment and respiratory failure may develop. Super-added infection is Tasteless and this is characterised by fever, cough, purulent sputum, and even hemoptysis. Though pulmonary osteoarthropathy may occur, it is a late feature. This is in discrepancy to bronchiectasis, in which clubbing is an early feature. Potential complications are infection, hemoptysis, Pneumothorax, fibrosis, and Cor Pulmonale.

Diagnosis
Cystic disease has to be suspected when a child presents with recurrent respiratory infections. presence of other congenital abnormalities should enlarge this suspicion. X-ray shows thin-walled cysts, which may be singular or multiple. Tuberculosis, bronchiectasis, and Lung abscess have to be differentiated. In congenital cystic lung bronchography delineates the lesions. In the case of singular non-communicating cysts, the dye does not enter the cavity.

Treatment
A large singular cysts producing respiratory embarrassment from infancy has to be excised. When the cysts are multiple, surgery is contraindicated. Healing supervision is on the same lines as for bronchiectasis.

Disease of the Pleura and Pulmonary CystsThe BATTLE Continues: Fighting Lung Cancer Video Clips. Duration : 2.47 Mins.

The BATTLE grant consists of an "umbrella trial" plus four phase II clinical trials. To be eligible for the BATTLE trials, patients must have a diagnosis of stage IIIB, stage IV, or advanced, incurable non-small cell lung cancer, confirmed by tumor biopsy and/or fine-needle aspiration, and have received at least one chemotherapy regimen. Umbrella Trial All patients who meet the eligibility criteria are enrolled in the Umbrella trial and undergo a tumor biomarker analysis, the results of which determine assignment to one of the four phase II clinical trials. The goal is to assign a patient to the clinical trial that offers the best benefit based on the characteristics of his/her tissue biomarker profile; in other words, treatment is individualized. Clinical Trials The primary objective of each of the four phase II clinical studies is to determine after the second cycle of treatment (eight weeks) if the patient's disease has progressed. This will be determined by chest X-ray, CT or MRI scan, and optional re-biopsy of the tumor. Patients with no progression of disease will continue on the treatment. Patients whose disease has progressed will not be eligible to continue treatment on that particular study, but will be eligible to pursue other treatments, such as one of the other BATTLE clinical trials: Erlotinib (Tarceva™): Patients will be treated with erlotinib once daily without interruption. A four week (28 days) period of treatment will be considered one cycle of therapy ...

Tags: drkim, lungresearch, withoutmayberry, my, Giving, To, mdanderson

lung aspiration

Monday, January 9, 2012